6 Cutaneous Skin Cancer 1 1 0 1 1 1260 http://clinicaltrials.dfhcc.harvard.edu/trials/1260 A Study Evaluating the Efficacy and Safety of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma This is a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the efficacy and safety of GDC-0449 in patients with advanced BCC. All patients will receive GDC-0449 until evidence of progression, intolerable toxicities most probably attributable to GDC-0449, or withdrawal from the study. Recruiting 6 Cutaneous Skin Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/6-cutaneous-skin-cancer Phase 2